An investigator-initiated, pragmatic, registry-based, multi-centre, double-blind, randomised controlled trial evaluating the effect of Plasmalyte versus 0.9% saline on early kidney transplant function in deceased donor kidney transplantation.
Intravenous fluids are a critical aspect of care when performing kidney transplants. Currently, isotonic sodium chloride (0.9% saline) is the standard of care in fluids at most transplant centres. This solution, however, may be harmful due to its high chloride content (relative to plasma) and may promote acute kidney injury which can lead to dangerous outcomes for the patient. The BEST-Fluids study is investigating a new fluid, Plasmalyte, to see if it is better than the standard O.9% saline solution in kidney transplants. If so, it may result in significant cost savings and offer better outcomes for kidney transplant patients.
We're inviting health professionals and study coordinators from sites who are attending the ANZSN ASM meeting to join us for a complementary, casual breakfast session on 12th September at 7.30 am. This will provide the perfect opportunity to give update on the study, and will be held close to the International Convention Centre in Sydney.
